Harini Bupathi, Esq, explains why pharmacies need to continue prioritizing PBM relationships despite rapid legislative change.
|Articles|May 17, 2004
FDA, JCAHO to drive growth of bedside scanning
The recent FDA bar code announcement, including National Drug Code (NDC) and JCAHO's plan to implement bar-coding prompts vendors to bring out offerings at breakneck speed.
Advertisement
Advertisement
Related to this article
Researchers assessed the extent of which vaccine fatigue translates to reduced engagement and adherence among patients.
Brianne Porter, PharmD, MS, explores how pharmacists can deliver care to a population of women experiencing life-altering symptoms of urinary incontinence.
AJ Barbarito, Esq, explains how ERISA and Medicare Part D preemption limit state PBM laws and why a private right of action may be the most effective path forward.
Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
Investigators link oversight with eroding trust in health authorities and call on future pandemic inquiries to weigh trade-offs.
Lara Zakaria, PharmD, MS, CNS, FMCP, illustrates the breadth of health technology going in and out of community pharmacy practice.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
Q&A: Why Enforcement Is the Weak Link in State PBM Reform | NCPA 2026
3
PBM Network Terminations Bring Risks Beyond Lost Contracts | NCPA 2026
4
FDA Approves Bepirovirsen Injection to Treat Chronic Hepatitis B
5